Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

22.06
-1.58 (-6.68%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :750,328
Date :10-15-2021

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed to Present at Cantor Fitzgerald Virtual Global Healthcare Conference

9月 23rd, 2021|Oramed to Present at Cantor Fitzgerald Virtual Global Healthcare Conference已关闭评论

NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP), (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav [...]

Oramed’s Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment

9月 15th, 2021|Oramed’s Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment已关闭评论

NEW YORK, Sept. 15, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that it has enrolled over 50% [...]

Oramed to Present at H.C. Wainwright 23rd Annual Global Investment Conference

9月 9th, 2021|Oramed to Present at H.C. Wainwright 23rd Annual Global Investment Conference已关闭评论

NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron [...]

Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials

8月 24th, 2021|Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials已关闭评论

- ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol currently underway - ORA-D-013-1, the larger and first of the 2-part trial to commence, nears 65% enrollment NEW YORK, Aug. 24, 2021 [...]